Work

Adherence-enhancing intervention and relapse in childhood acute lymphoblastic leukemia: results from the Children’s Oncology Group randomized trial ACCL1033

Year: 2026
Type: article
Study design: Clinical Trial
Abstract: Durable remissions in children with acute lymphoblastic leukemia (ALL) require an 18-to-24-month-long maintenance phase with daily self-administered oral mercaptopurine (6MP) [ 1 , 2 , 3 , 4 ]. In a previous multicenter study, we showed that 6MP adherence rates <95% were associated with a 2.7-fold higher relapse risk [ 4 ]. Over 40% of relapses in children entering maintenance in first remission were attributable to suboptimal 6MP adherence [ 4 , 5 , 6 ]. The most common reason for missing 6MP was forgetfulness [ 5 ]; adherent patients endorsed parental vigilance to overcome forgetfulness [ 7 ].
Source: Leukemia
Language: English
Field: Medicine
Open Access status: hybrid
Estimated APC paid: $5,190
OpenAlex ID: W7154073254
FWCI:
Cites: 11
Cited by:
Related to: